Related Experiment Video
Updated: Dec 20, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas
Lindsay Scheetz1,2, Padma Kadiyala3, Xiaoqi Sun1,2
1Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan.
Purpose:
Gliomas are brain tumors with dismal prognoses. The standard-of-care treatments for gliomas include surgical resection, radiation, and temozolomide administration; however, they have been ineffective in providing significant increases in median survival. Antigen-specific cancer vaccines and immune checkpoint blockade may provide promising immunotherapeutic approaches for gliomas.
Experimental Design:
We have developed immunotherapy delivery vehicles based on synthetic high-density lipoprotein (sHDL) loaded with CpG, a Toll-like receptor-9 agonist, and tumor-specific neoantigens to target gliomas and elicit immune-mediated tumor regression.
Results:
We demonstrate that vaccination with neoantigen peptide-sHDL/CpG cocktail in combination with anti-PD-L1 immune checkpoint blocker elicits robust neoantigen-specific T-cell responses against GL261 cells and eliminated established orthotopic GL261 glioma in 33% of mice. Mice remained tumor free upon tumor cell rechallenge in the contralateral hemisphere, indicating the development of immunologic memory. Moreover, in a genetically engineered murine model of orthotopic mutant IDH1 (mIDH1) glioma, sHDL vaccination with mIDH1 neoantigen eliminated glioma in 30% of animals and significantly extended the animal survival, demonstrating the versatility of our approach in multiple glioma models.
Conclusions:
Overall, our strategy provides a general roadmap for combination immunotherapy against gliomas and other cancer types.
Insights
This study developed synthetic high-density lipoprotein (sHDL) nanoparticles for glioma immunotherapy. Combination therapy with sHDL vaccines and immune checkpoint blockade shows promise in eliminating brain tumors and establishing long-term immunity.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Nanotechnology
Background:
- Gliomas are aggressive brain tumors with poor prognoses despite standard treatments.
- Current therapies like surgery, radiation, and temozolomide offer limited survival benefits.
- Novel immunotherapeutic strategies are urgently needed for effective glioma treatment.
Purpose of the Study:
- To develop and evaluate a novel immunotherapy delivery system for targeting gliomas.
- To investigate the efficacy of synthetic high-density lipoprotein (sHDL) nanoparticles loaded with CpG and neoantigens.
- To assess the combination of sHDL-based immunotherapy with immune checkpoint blockade for glioma regression.
Main Methods:
- Developed sHDL nanoparticles encapsulating CpG (Toll-like receptor-9 agonist) and tumor-specific neoantigens.
- Administered sHDL/CpG vaccine in combination with anti-PD-L1 immune checkpoint blockade in GL261 glioma models.
- Evaluated treatment efficacy through tumor elimination, survival extension, and immunologic memory assessment.
- Tested the approach in a separate genetically engineered murine model of mutant IDH1 (mIDH1) glioma.
Main Results:
- Combination therapy eradicated established orthotopic GL261 gliomas in 33% of mice.
- Treated mice developed immunologic memory, resisting tumor rechallenge.
- In mIDH1 glioma models, sHDL vaccination eliminated tumors in 30% of animals and significantly improved survival.
- Demonstrated the versatility of the sHDL platform across different glioma models.
Conclusions:
- The developed sHDL-based immunotherapy strategy shows significant potential for treating gliomas.
- Combination therapy with sHDL vaccines and immune checkpoint inhibitors offers a promising approach for glioma regression.
- This strategy provides a generalizable roadmap for combination immunotherapy in gliomas and other cancers.
